Ticker
XNCR
Analysis
Xencor, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to XNCR.
Xencor, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to XNCR.
XNCR
Stock
$937.1M
Health Technology
Biotechnology
USD
Xencor, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.
-- XmAb819 clear cell renal cell carcinoma (ccRCC) expansion cohort results to be presented at a medical conference in 2H26 -- -- XmAb412 (TL1A x IL23p19)
PASADENA, Calif., May 04, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmun...
PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment
-- XmAb819, novel first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody, Phase 1 dose expansion in CRC, NSCLC and pRCC open to enrollment; on track
PASADENA, Calif., January 08, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoi...
Review valuation context for Xencor, Inc..
Review future growth context for Xencor, Inc..
Review past performance context for Xencor, Inc..
Review financial health context for Xencor, Inc..
Review dividend context for Xencor, Inc..
Review management context for Xencor, Inc..
Review ownership context for Xencor, Inc..
Review other information context for Xencor, Inc..
Review community context for Xencor, Inc..